Express News | The US 'Biological Safety Law' was not included in the US Senate's '2025 Fiscal Year National Defense Authorization Act'.
Express News | The expert review pass rate for varieties outside the medical insurance catalog is less than 50%, and the requirements for innovative drugs may need to be increased.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
①The growth rate of total sales revenue of retail pharmacies has slowed down, and the competition continues to intensify. In the first half of this year, major leading chain drugstores found it difficult to increase revenue and profit; ②In the future, the focus of pharmacy competition will shift to product extension and services. According to Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all terminals is expected to decrease to 4.9% in 2024, compared to the decline in 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
① At the 2024 New Investment Conference hosted by Forrester Sullivan, the issue of going global was highly favored by the participants. ② There is a new trend in the global expansion of innovative drugs in our country, such as the number of BDs going global surpassing License-in for the first time in 2023. ③ Some experts at the conference proposed a rational view and called for the need to strengthen internal capabilities, not just rely on enthusiasm.
Enter the field of cosmetics, pay attention to the marginal changes and value enhancement behind the expansion of pharmaceutical industry B (9939.HK)
Currently, the innovative drug industry is still going through a winter moment and the "water shortage" dilemma it faces has not been fundamentally alleviated. Many companies have to make difficult decisions such as selling pipelines and selling equities. In this stage, how can innovative drug enterprises break through? Recently, KaiTuo Pharmaceutical released its mid-term financial report for 2024, with a significant reduction in net loss by 66.3% in the first half of the year, and research and development costs and administrative expenses decreased by 76.1% and 33.8% respectively compared to the same period last year. At the same time, the company's cash and cash equivalents as well as time deposits are approximately 0.34 billion yuan, with ample cash on hand. Through the financial report, it can be seen that as a long-time player in the field of innovative drugs,
The revenue of Concord Medical (09939.HK) narrowed to 71.49 million RMB in the first half of the year.
Kaituo Pharmaceutical - B (09939.HK) announced its interim performance for the six months ending in June. The loss narrowed from RMB 0.212 billion in the same period last year to RMB 71.49 million, with a loss per share of 17 cents. No interim dividend was distributed. No revenue was recorded during the period.
Kaituo Pharmaceutical-B (09939.HK) announced its interim performance with a significant reduction in losses. It is expected to launch seven cosmetics in 2024.
Kaituo Pharmaceutical - B (09939.HK) announcement, for the six months ended June 30, 2024, the company's net loss decreased by RMB 14.06 million or 66.3% from RMB 21.21 million in the same period last year to RMB 7.15 million during the period. The decrease in such losses was mainly due to a reduction in the group's research and development costs and administrative expenses.
Kaituo Pharmaceuticals-B (09939) released its interim performance, with a shareholder's attributable loss of 71.493 million yuan, a year-on-year narrowing of 66.29%.
KaiTuo Pharmaceutical - B (09939) announces its interim performance for the six months ended June 30, 2024. During this period, the group...
KINTOR PHARMA-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Express News | Economic Daily: Enhancing the original innovation of the biomedical industry.
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Kaituo Pharmaceutical-B (09939.HK) held a board of directors meeting on August 26 to consider and approve its interim performance.
Kaituo Pharmaceutical-B (09939.HK) announced on August 9 that the board of directors meeting will be held on August 26, 2024 (Monday) to consider and approve the mid-term performance of the company and its subsidiaries ending on June 30, 2024, including its release.
KINTOR PHARMA-B: DATE OF BOARD MEETING
Express News | China Securities Co., Ltd.: Focus on six directions of investment opportunities in the pharmaceutical industry.
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Over 400 pharmaceuticals selected! The preliminary list of the 2024 National Drug Reimbursement List has been published. Experts predict that the threshold for innovative drugs may be lowered.
This year, 440 pharmaceuticals were preliminarily reviewed and included in the drug list for national medical insurance negotiations, with 196 and 244 pharmaceuticals inside and outside the catalog respectively. Many of the applied drugs are innovative drugs that will be launched in June. Several of them have preemptively reduced their prices to increase the probability of successful negotiations. Based on supportive policies, experts predict that the threshold for access to innovative drugs may be lowered this year, and the number of them may increase.
The list of initial review of the national dialogue in 2024 has been announced! Many heavyweight innovative drugs are listed, and almost all CAR-T varieties are gathered. Will there be breakthroughs? | Industry observation
This evening, the National Medical Insurance Bureau announced the list of drugs that passed the preliminary review of the national negotiations this year. The bureau received 626 applications from enterprises, and 440 drugs passed the preliminary review. Several heavy-weight innovative drugs have been approved by the wire or reduced in price, which is considered by the industry as the most important channel for the commercial realization of innovative drugs through medical insurance eligibility. Almost all types of domestic CAR-T are gathered, and experts predict that there may be breakthroughs this year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
No Data
No Data